Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Nab-Sirolimus and Fulvestrant for the Treatment of Recurrent Low Grade Serous Ovarian Cancer

Trial Status: active

This phase II trial tests the safety and effectiveness of nab-sirolimus plus fulvestrant for treating low grade serous ovarian cancer that has come back after a period of improvement (recurrent). Sirolimus is a kinase inhibitor. It blocks the activity of certain pathways in the body that may cause a decrease in tumor cell multiplication. Nab-sirolimus is an albumin-stabilized nanoparticle formulation of sirolimus, which may have fewer side effects and work better than other forms of sirolimus. Fulvestrant is a type of hormone therapy. It binds to estrogen receptors, resulting in estrogen receptor deformation and decreased estrogen binding. Nab-sirolimus is approved for the treatment of other types of cancer and fulvestrant is approved for the treatment of breast cancer, but neither of these drugs are approved for the treatment of ovarian cancer. The combination of these drugs may be a safe and effective treatment option for patients with recurrent low grade serous ovarian cancer.